+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Influenza Treatment Market Size, Share & Trends Analysis Report by Treatment (Peramivir, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate), Route Of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 130 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5921085
Description Jump to:
The global influenza treatment market is expected to reach USD 6.44 billion by 2030, expanding at a CAGR of 1.18% from 2024 to 2030. The growth of the market is attributed to the rising prevalence of influenza aided by the rising need for efficient therapeutics to treat the condition. Furthermore, key players are constantly focusing on developing novel therapeutics to meet the rising demand for precise medication with constant initiative by the FDA for approval of influenza treatment drugs. As a result of which, the constant demand for treatment globally is fueling the growth of the overall market.

Additionally, the rising prevalence of seasonal flu and respiratory diseases has boosted the demand for novel therapeutics. According to CDC, it is estimated that the burden of flu in the U.S. had resulted in 9 million -41 million illnesses, 140,000 - 710,000 hospitalizations, and 12,000 - 52,000 deaths yearly between 2010 and 2020. Similarly, according to preliminary results around 9 million individuals had symptomatic illnesses, and approximately 4 million medical visits, 100,000 hospitalizations, and 5 thousand deaths were reported from 2021 to 2022.

The market growth is expected to be driven by the increasing approval and upcoming commercialization of innovative medications for viral infections. For instance, in August 2022, Roche announced the U.S. FDA approval for Xofluza (baloxavir marboxil), used for the treatment of acute influenza in children aged 5 to 12 years who have been symptomatic for 48 hours. Additionally, prominent players in the industry have introduced several novel medicines for viral infections within the span of 2 to 3 years propelling the need for the development of novel medication by other small players operating in the market in order to generate significant revenue share.

Moreover, the COVID-19 pandemic has significantly boosted the growth of the market. During the pandemic, the demand for broad-spectrum antiviral drugs to combat the novel coronavirus has surged due to the need to manage the disease effectively. Medications like Remdesivir, favipiravir, oseltamivir, and various combination therapies have become widely prescribed for treating COVID-19. Additionally, governments are allocating greater funding to pharmaceutical companies to expedite the development of novel therapeutics against COVID-19. For instance, in June 2021, the U.S. government announced an investment of over USD 3 billion to accelerate the discovery, manufacturing, and development of antiviral medicines. As the incidence of the disease continues to rise and research and development efforts intensify, the demand for antiviral drugs is expected to increase in the next 2 to 3 years.

Furthermore, the key participants are engaged in various strategies such as product launches, partnerships & collaborations, and mergers & acquisitions, to expand their global footprints and maintain their competitive position in the influenza treatment market. For instance, in November 2020, Shionogi’s XOFLUZA (Baloxavir Marboxil) received FDA approval for the prevention of influenza. Similarly, in February 2021, FDA expanded the approval of Rapivab which is a peramivir injection, a product of BioCryst Pharmaceuticals. The product is extensively used for treating acute uncomplicated influenza in 6 months of age & older patients who have been symptomatic for 2 days.

Influenza Treatment Market Report Highlights

  • Based on treatment, the oseltamivir phosphate segment held the largest revenue share in 2023 in the market owing to the rising prevalence of influenza leading to increasing prescription of oseltamivir phosphate
  • Based on route of administration, the oral segment dominated the market with a revenue share in 2023 attributed to the increased adoption of oral drug products due to their ease of administration
  • On the basis of distribution channel, the hospital pharmacy segment dominated the market in 2023 due to the rising hospitalization and use of hospital pharmacies for medication
  • North America held the largest share in 2023 owing to the presence of well-established players, the rising prevalence of seasonal flu, and an increased hospitalization due to the condition

Table of Contents

Chapter 1. Influenza Treatment Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Treatment Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Influenza Treatment Market: Executive Summary
2.1. Market Snapshot
2.2. Treatment and Route of Administration Snapshot
2.3. Distribution Channel Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Influenza Treatment Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising new FDA-approved influenza treatment drugs
3.4.2. Prevalence of contagious respiratory illness such as influenza
3.5. Market Restraint Analysis
3.5.1. Complicated conditions associated with influenza treatment
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
Chapter 4. Influenza Treatment Market: Treatment Estimates & Trend Analysis
4.1. Influenza Treatment Market: Treatment Movement Analysis
4.2. Peramivir
4.2.1. Peramivir Market Estimates and Forecasts, 2018-2030 (USD Million)
4.3. Zanamivir
4.3.1. Zanamivir Market Estimates and Forecasts, 2018-2030 (USD Million)
4.4. Baloxavir Marboxil
4.4.1. Baloxavir Marboxil Market Estimates and Forecasts, 2018-2030 (USD Million)
4.5. Oseltamivir Phosphate
4.5.1. Oseltamivir Phosphate Market Estimates and Forecasts, 2018-2030 (USD Million)
4.6. Others
4.6.1. Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Influenza Treatment Market: Route of Administration Estimates & Trend Analysis
5.1. Influenza Treatment Market: Route of Administration Movement Analysis
5.2. Oral
5.2.1. Oral Market Estimates and Forecasts, 2018-2030 (USD Million)
5.3. Others
5.3.1. Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 6. Influenza Treatment Market: Distribution Channel Estimates & Trend Analysis
6.1. Influenza Treatment Market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacies
6.2.1. Hospital Pharmacies Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3. Retail Pharmacies
6.3.1. Retail Pharmacies Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4. Online Pharmacies
6.4.1. Online Pharmacies Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Influenza Treatment Market: Regional Business Analysis
7.1. Regional Market Snapshot
7.2. North America
7.2.1. North America Influenza Treatment Market Estimates And Forecast, 2018-2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Influenza Treatment Market, 2018-2030 (USD Million)
7.2.2.2. Key Country Dynamics
7.2.2.3. Regulatory Framework
7.2.2.4. Reimbursement Scenario
7.2.2.5. Competitive Scenario
7.2.3. Canada
7.2.3.1. Canada Influenza Treatment Market, 2018-2030 (USD Million)
7.2.3.2. Key Country Dynamics
7.2.3.3. Regulatory Framework
7.2.3.4. Reimbursement Scenario
7.2.3.5. Competitive Scenario
7.3. Europe
7.3.1. Europe Influenza Treatment Market, 2018-2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Influenza Treatment Market, 2018-2030 (USD Million)
7.3.2.2. Key Country Dynamics
7.3.2.3. Regulatory Framework
7.3.2.4. Reimbursement Scenario
7.3.2.5. Competitive Scenario
7.3.3. Germany
7.3.3.1. Germany Influenza Treatment Market, 2018-2030 (USD Million)
7.3.3.2. Key Country Dynamics
7.3.3.3. Regulatory Framework
7.3.3.4. Reimbursement Scenario
7.3.3.5. Competitive Scenario
7.3.4. France
7.3.4.1. France Influenza Treatment Market, 2018-2030 (USD Million)
7.3.4.2. Key Country Dynamics
7.3.4.3. Regulatory Framework
7.3.4.4. Reimbursement Scenario
7.3.4.5. Competitive Scenario
7.3.5. Italy
7.3.5.1. Italy Influenza Treatment Market, 2018-2030 (USD Million)
7.3.5.2. Key Country Dynamics
7.3.5.3. Regulatory Framework
7.3.5.4. Reimbursement Scenario
7.3.5.5. Competitive Scenario
7.3.6. Spain
7.3.6.1. Spain Influenza Treatment Market, 2018-2030 (USD Million)
7.3.6.2. Key Country Dynamics
7.3.6.3. Regulatory Framework
7.3.6.4. Reimbursement Scenario
7.3.6.5. Competitive Scenario
7.3.7. Denmark
7.3.7.1. Denmark Influenza Treatment Market, 2018-2030 (USD Million)
7.3.7.2. Key Country Dynamics
7.3.7.3. Regulatory Framework
7.3.7.4. Reimbursement Scenario
7.3.7.5. Competitive Scenario
7.3.8. Norway
7.3.8.1. Norway Influenza Treatment Market, 2018-2030 (USD Million)
7.3.8.2. Key Country Dynamics
7.3.8.3. Regulatory Framework
7.3.8.4. Reimbursement Scenario
7.3.8.5. Competitive Scenario
7.3.9. Sweden
7.3.9.1. Sweden Influenza Treatment Market, 2018-2030 (USD Million)
7.3.9.2. Key Country Dynamics
7.3.9.3. Regulatory Framework
7.3.9.4. Reimbursement Scenario
7.3.9.5. Competitive Scenario
7.4. Asia-Pacific
7.4.1. Asia-pacific Influenza Treatment Market, 2018-2030 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Influenza Treatment Market, 2018-2030 (USD Million)
7.4.2.2. Key Country Dynamics
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Scenario
7.4.2.5. Competitive Scenario
7.4.3. China
7.4.3.1. China Influenza Treatment Market, 2018-2030 (USD Million)
7.4.3.2. Key Country Dynamics
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Scenario
7.4.3.5. Competitive Scenario
7.4.4. India
7.4.4.1. India Influenza Treatment Market, 2018-2030 (USD Million)
7.4.4.2. Key Country Dynamics
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Scenario
7.4.4.5. Competitive Scenario
7.4.5. South Korea
7.4.5.1. South Korea Influenza Treatment Market, 2018-2030 (USD Million)
7.4.5.2. Key Country Dynamics
7.4.5.3. Regulatory Framework
7.4.5.4. Reimbursement Scenario
7.4.5.5. Competitive Scenario
7.4.6. Australia
7.4.6.1. Australia Influenza Treatment Market, 2018-2030 (USD Million)
7.4.6.2. Key Country Dynamics
7.4.6.3. Regulatory Framework
7.4.6.4. Reimbursement Scenario
7.4.6.5. Competitive Scenario
7.4.7. Thailand
7.4.7.1. Thailand Influenza Treatment Market, 2018-2030 (USD Million)
7.4.7.2. Key Country Dynamics
7.4.7.3. Regulatory Framework
7.4.7.4. Reimbursement Scenario
7.4.7.5. Competitive Scenario
7.5. Latin America
7.5.1. Latin America Influenza Treatment Market, 2018-2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Influenza Treatment Market, 2018-2030 (USD Million)
7.5.2.2. Key Country Dynamics
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Scenario
7.5.2.5. Competitive Scenario
7.5.3. Mexico
7.5.3.1. Mexico Influenza Treatment Market, 2018-2030 (USD Million)
7.5.3.2. Key Country Dynamics
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Scenario
7.5.3.5. Competitive Scenario
7.5.4. Argentina
7.5.4.1. Argentina Influenza Treatment Market, 2018-2030 (USD Million)
7.5.4.2. Key Country Dynamics
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Scenario
7.5.4.5. Competitive Scenario
7.6. MEA
7.6.1. MEA Influenza Treatment Market, 2018-2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Influenza Treatment Market, 2018-2030 (USD Million)
7.6.2.2. Key Country Dynamics
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Scenario
7.6.2.5. Competitive Scenario
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Influenza Treatment Market, 2018-2030 (USD Million)
7.6.3.2. Key Country Dynamics
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Scenario
7.6.3.5. Competitive Scenario
7.6.4. UAE
7.6.4.1. UAE Influenza Treatment Market, 2018-2030 (USD Million)
7.6.4.2. Key Country Dynamics
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Scenario
7.6.4.5. Competitive Scenario
7.6.5. Kuwait
7.6.5.1. Kuwait Influenza Treatment Market, 2018-2030 (USD Million)
7.6.5.2. Key Country Dynamics
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Scenario
7.6.5.5. Competitive Scenario
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. New Launch
8.2.2. Partnerships
8.2.3. Acquisition
8.2.4. Collaboration
8.3. Key Company Market Share Analysis, 2023
8.4. Company Heat Map Analysis
8.5. Company Profiles
8.5.1. Natco Pharma Limited
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Novartis Ag
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. F. Hoffmann-la Roche Ltd
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Biocryst Pharmaceuticals, Inc.
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Sanofi
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Gsk Plc.
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Viatris Inc. (Mylan)
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Teva Pharmaceutical Industries Ltd.
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Daiichi Sankyo Company, Limited.
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Astrazeneca
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Global Influenza Treatment Market, By Region, 2018-2030 (USD Million)
Table 4 North America Influenza Treatment Market, By Country, 2018-2030 (USD Million)
Table 5 North America Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 6 North America Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 7 North America Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 8 U.S. Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 9 U.S. Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 10 U.S. Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 11 Canada Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 12 Canada Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 13 Canada Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 14 Europe Influenza Treatment Market, By Country, 2018-2030 (USD Million)
Table 15 Europe Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 16 Europe Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 17 Europe Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 18 Germany Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 19 Germany Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 20 Germany Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 21 UK Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 22 UK Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 23 UK Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 24 France Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 25 France Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 26 France Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 27 Spain Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 28 Spain Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 29 Spain Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 30 Italy Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 31 Italy Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 32 Italy Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 33 Denmark Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 34 Denmark Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 35 Denmark Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 36 Norway Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 37 Norway Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 38 Norway Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 39 Sweden Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 40 Sweden Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 41 Sweden Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 42 Asia-Pacific Influenza Treatment Market, By Country, 2018-2030 (USD Million)
Table 43 Asia-Pacific Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 44 Asia-Pacific Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 45 Asia-Pacific Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 46 Japan Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 47 Japan Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 48 Japan Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 49 China Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 50 China Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 51 China Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 52 India Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 53 India Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 54 India Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 55 Australia Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 56 Australia Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 57 Australia Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 58 South Korea Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 59 South Korea Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 60 South Korea Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 61 Thailand Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 62 Thailand Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 63 Thailand Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 64 Latin America Influenza Treatment Market, By Country, 2018-2030 (USD Million)
Table 65 Latin America Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 66 Latin America Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 67 Latin America Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 68 Brazil Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 69 Brazil Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 70 Brazil Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 71 Mexico Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 72 Mexico Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 73 Mexico Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 74 Argentina Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 75 Argentina Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 76 Argentina Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 77 Middle East & Africa Influenza Treatment Market, By Country, 2018-2030 (USD Million)
Table 78 Middle East & Africa Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 79 Middle East & Africa Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 80 Middle East & Africa Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 81 Saudi Arabia Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 82 Saudi Arabia Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 83 Saudi Arabia Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 84 South Africa Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 85 South Africa Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 86 South Africa Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 87 UAE Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 88 UAE Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 89 UAE Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
Table 90 Kuwait Influenza Treatment Market, By Treatment, 2018-2030 (USD Million)
Table 91 Kuwait Influenza Treatment Market, By Route of Administration, 2018-2030 (USD Million)
Table 92 Kuwait Influenza Treatment Market, By Distribution Channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Market summary
Figure 4 Market segmentation & scope
Figure 5 Market size and growth prospects
Figure 6 Global influenza treatment market- Key market driver analysis
Figure 7 Global influenza treatment market - Key market restraint analysis
Figure 8 Penetration & growth prospect mapping
Figure 9 Global influenza treatment market - Porter’s analysis
Figure 10 Global influenza treatment market - PESTEL analysis
Figure 11 Global influenza treatment market: Treatment outlook key takeaways
Figure 12 Global influenza treatment market: Treatment movement analysis
Figure 13 Peramivir market estimates and forecast, 2018-2030 (USD Million)
Figure 14 Zanamivir market estimates and forecast, 2018-2030 (USD Million)
Figure 15 Baloxavir marboxil market estimates and forecast, 2018-2030 (USD Million)
Figure 16 Oseltamivir phosphate market estimates and forecast, 2018-2030 (USD Million)
Figure 17 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 18 Global influenza treatment market: Route of Administration outlook key takeaways
Figure 19 Global influenza treatment market: Route of Administration movement analysis
Figure 20 Oral market estimates and forecast, 2018-2030 (USD Million)
Figure 21 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 22 Global influenza treatment market: Distribution Channel outlook key takeaways
Figure 23 Global influenza treatment market: Distribution Channel movement analysis
Figure 24 Hospital pharmacies market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Retail pharmacies market estimates and forecast, 2018-2030 (USD Million)
Figure 26 Online pharmacies market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Regional marketplace: Key takeaways
Figure 28 Global influenza treatment market: Regional movement analysis
Figure 29 North America influenza treatment market, 2018-2030 (USD Million)
Figure 30 U.S. influenza treatment market, 2018-2030 (USD Million)
Figure 31 Canada influenza treatment market, 2018-2030 (USD Million)
Figure 32 Europe influenza treatment market, 2018-2030 (USD Million)
Figure 33 UK influenza treatment market, 2018-2030 (USD Million)
Figure 34 Germany influenza treatment market, 2018-2030 (USD Million)
Figure 35 France influenza treatment market, 2018-2030 (USD Million)
Figure 36 Italy influenza treatment market, 2018-2030 (USD Million)
Figure 37 Spain influenza treatment market, 2018-2030 (USD Million)
Figure 38 Denmark influenza treatment market, 2018-2030 (USD Million)
Figure 39 Norway influenza treatment market, 2018-2030 (USD Million)
Figure 40 Sweden influenza treatment market, 2018-2030 (USD Million)
Figure 41 Asia-Pacific influenza treatment market, 2018-2030 (USD Million)
Figure 42 Japan influenza treatment market, 2018-2030 (USD Million)
Figure 43 China influenza treatment market, 2018-2030 (USD Million)
Figure 44 India influenza treatment market, 2018-2030 (USD Million)
Figure 45 South Korea influenza treatment market, 2018-2030 (USD Million)
Figure 46 Australia influenza treatment market, 2018-2030 (USD Million)
Figure 47 Thailand influenza treatment market, 2018-2030 (USD Million)
Figure 48 Latin America influenza treatment market, 2018-2030 (USD Million)
Figure 49 Brazil influenza treatment market, 2018-2030 (USD Million)
Figure 50 Mexico influenza treatment market, 2018-2030 (USD Million)
Figure 51 Argentina influenza treatment market, 2018-2030 (USD Million)
Figure 52 MEA influenza treatment market, 2018-2030 (USD Million)
Figure 53 South Africa influenza treatment market, 2018-2030 (USD Million)
Figure 54 Saudi Arabia influenza treatment market, 2018-2030 (USD Million)
Figure 55 UAE influenza treatment market, 2018-2030 (USD Million)
Figure 56 Kuwait influenza treatment market, 2018-2030 (USD Million)
Figure 57 Strategy framework

Companies Mentioned

  • Natco Pharma Limited
  • Novartis Ag
  • F. Hoffmann-la Roche Ltd
  • Biocryst Pharmaceuticals, Inc.
  • Sanofi
  • Gsk Plc.
  • Viatris Inc. (Mylan)
  • Teva Pharmaceutical Industries Ltd.
  • Daiichi Sankyo Company, Limited.
  • Astrazeneca

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages130
PublishedDecember 2023
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 5.91 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.44 Billion
Compound Annual Growth Rate1.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Influenza Treatment Global Market Report 2024 - Product Image

Influenza Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Influenza A virus H5N1 subtype - Pipeline Insight, 2024 - Product Image

Influenza A virus H5N1 subtype - Pipeline Insight, 2024

  • Drug Pipelines
  • 40 Pages
  • Global
From
Influenza Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Influenza Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 102 Pages
  • Global
From
Oseltamivir Phosphate Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Oseltamivir Phosphate Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 86 Pages
  • Global
From
Oseltamivir (CAS 196618-13-0) Global Market Research Report 2024 - Product Image

Oseltamivir (CAS 196618-13-0) Global Market Research Report 2024

  • Report
  • 50 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.